

# Patrick Rossignol

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1441587/publications.pdf>

Version: 2024-02-01

68  
papers

1,578  
citations

361413

20  
h-index

315739

38  
g-index

71  
all docs

71  
docs citations

71  
times ranked

2486  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHEBUS trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 380-392.	3.3	6
2	Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	6
3	Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?. <i>European Journal of Heart Failure</i> , 2022, 24, 631-633.	7.1	0
4	Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARICâ€“WHO clinical characterisation protocol. <i>PLoS Medicine</i> , 2022, 19, e1003969.	8.4	10
5	Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20â€“Year Followâ€“Up. <i>Journal of the American Heart Association</i> , 2022, 11, e023301.	3.7	1
6	Estimated plasma volume status in heart failure: clinical implications and future directions. <i>Clinical Research in Cardiology</i> , 2021, 110, 1159-1172.	3.3	30
7	Should reninâ€“angiotensinâ€“aldosterone system inhibition enablement be a therapeutic target in CKD patients?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1771-1772.	0.7	0
8	The value of spot urinary creatinine as a marker of muscle wasting in patients with newâ€“onset or worsening heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 555-567.	7.3	15
9	Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program. <i>Drugs - Real World Outcomes</i> , 2021, 8, 315-323.	1.6	13
10	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1308-1320.	3.3	3
11	Heart Failure and Chronic Kidney Disease Patients. <i>Journal of the American College of Cardiology</i> , 2021, 78, 344-347.	2.8	4
12	Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort. <i>Clinical Cardiology</i> , 2021, 44, 1516-1525.	1.8	7
13	A Step Forward Toward a New Treatment Paradigm in the Cardiorenal Continuum. <i>JACC: Heart Failure</i> , 2021, 9, 821-823.	4.1	0
14	A Combination of Chest Radiography and Estimated Plasma Volume May Predict In-Hospital Mortality in Acute Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 752915.	2.4	5
15	Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study. <i>International Journal of Cardiology</i> , 2020, 299, 192-198.	1.7	14
16	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1402-1411.	7.1	19
17	Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 660-670.	1.6	21
18	Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners. <i>ESC Heart Failure</i> , 2020, 7, 2042-2050.	3.1	4

#	ARTICLE	IF	CITATIONS
19	Hypokalemia is frequent and has prognostic implications in stable patients attending the emergency department. PLoS ONE, 2020, 15, e0236934.	2.5	6
20	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (<sc><b>AMBER</b></sc>): results in the pre-specified subgroup with heart failure. European Journal of Heart Failure, 2020, 22, 1462-1471.	7.1	27
21	Hypo- and hyperkalaemia in heart failure. Navigating between Scylla and Charybdis. European Journal of Heart Failure, 2020, 22, 1399-1401.	7.1	0
22	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
23	Prognostic impact of plasma volume estimated from hemoglobin and hematocrit in heart failure with preserved ejection fraction. Clinical Research in Cardiology, 2020, 109, 1392-1401.	3.3	21
24	Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post-discharge. ESC Heart Failure, 2020, 7, 1257-1263.	3.1	9
25	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. European Journal of Heart Failure, 2020, 22, 1378-1389.	7.1	83
26	Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up. American Journal of Hypertension, 2020, 33, 869-878.	2.0	16
27	Diagnostic performance of congestion score index evaluated from chest radiography for acute heart failure in the emergency department: A retrospective analysis from the PARADISE cohort. PLoS Medicine, 2020, 17, e1003419.	8.4	10
28	Title is missing!. , 2020, 17, e1003419.		0
29	Title is missing!. , 2020, 17, e1003419.		0
30	Title is missing!. , 2020, 17, e1003419.		0
31	Title is missing!. , 2020, 17, e1003419.		0
32	Title is missing!. , 2020, 17, e1003419.		0
33	Title is missing!. , 2020, 15, e0236934.		0
34	Title is missing!. , 2020, 15, e0236934.		0
35	Title is missing!. , 2020, 15, e0236934.		0
36	Title is missing!. , 2020, 15, e0236934.		0

#	ARTICLE	IF	CITATIONS
37	The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. <i>Kidney International</i> , 2019, 95, 747-749.	5.2	22
38	Heart failure drug treatment. <i>Lancet</i> , The, 2019, 393, 1034-1044.	13.7	233
39	A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology. <i>European Heart Journal Supplements</i> , 2019, 21, A48-A54.	0.1	12
40	Management of hyperkalemia in the acutely ill patient. <i>Annals of Intensive Care</i> , 2019, 9, 32.	4.6	74
41	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , 2019, 108, 1215-1225.	3.3	17
42	Extracting Meaning of Tubular Injury Molecules: Implications for Cardiorenal Health. <i>American Journal of Nephrology</i> , 2019, 49, 343-345.	3.1	0
43	Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. <i>International Journal of Cardiology</i> , 2019, 289, 91-98.	1.7	21
44	Renal function, electrolytes, and congestion monitoring in heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M25-M31.	0.1	11
45	Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients. <i>JACC: Heart Failure</i> , 2019, 7, 33-35.	4.1	3
46	Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVEAL study. <i>ESC Heart Failure</i> , 2019, 6, 70-79.	3.1	4
47	Diagnostic and prognostic value of plasma volume status at emergency department admission in dyspneic patients: results from the PARADISE cohort. <i>Clinical Research in Cardiology</i> , 2019, 108, 563-573.	3.3	34
48	Cohort Profile: Rationale and design of the fourth visit of the STANISLAS cohort: a familial longitudinal population-based cohort from the Nancy region of France. <i>International Journal of Epidemiology</i> , 2018, 47, 395-395j.	1.9	33
49	Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population-based study. <i>European Journal of Heart Failure</i> , 2018, 20, 1066-1068.	7.1	8
50	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2018, 20, 323-331.	7.1	23
51	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. <i>Clinical Research in Cardiology</i> , 2018, 107, 214-221.	3.3	28
52	Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. <i>JACC: Heart Failure</i> , 2018, 6, 273-285.	4.1	152
53	Hyponatraemia, hyperglycaemia and worsening renal function at first blood sample on emergency department admission as predictors of in-hospital death in patients with dyspnoea with suspected acute heart failure: retrospective observational analysis of the PARADISE cohort. <i>BMJ Open</i> , 2018, 8, e019557.	1.9	10
54	Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings. <i>European Journal of Heart Failure</i> , 2018, 20, 1300-1302.	7.1	4

#	ARTICLE	IF	CITATIONS
55	Reply. JACC: Heart Failure, 2018, 6, 442-443.	4.1	1
56	The association between serum potassium and mortality in patients with hypertension: â€˜a wake-up callâ€™™. European Heart Journal, 2017, 38, ehw209.	2.2	13
57	Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey. Nephrology Dialysis Transplantation, 2017, 32, 2112-2118.	0.7	29
58	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure, 2017, 19, 792-799.	7.1	34
59	Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia. Pharmacological Research, 2017, 118, 2-4.	7.1	26
60	Renal function estimation and Cockcroftâ€™Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€™OMicsâ€™™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 2016, 14, 181.	5.5	48
61	Prognostic value of pulmonary congestion assessed by lung ultrasound imaging during heart failure hospitalisation: A two-centre cohort study. Scientific Reports, 2016, 6, 39426.	3.3	51
62	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Pharmacological Research, 2016, 113, 585-591.	7.1	91
63	Roadmap for cardiovascular prevention trials in chronic kidney disease. Lancet, The, 2016, 388, 1964-1966.	13.7	13
64	Intimaâ€™Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Populationâ€™Based Cohort (STANISLAS Cohort Study). Journal of the American Heart Association, 2016, 5, .	3.7	62
65	Left-to-right atrial shunting: new hope for heart failure?. Lancet, The, 2016, 387, 1253-1255.	13.7	4
66	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the <scp>GISSIâ€™CHF</scp> and Valâ€™HeFT</scp> trials. European Journal of Heart Failure, 2015, 17, 424-433.	7.1	104
67	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2015, 115, 790-796.	1.6	37
68	Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries. International Journal of Cardiology, 2014, 177, 731-733.	1.7	19